These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 16102108)
1. Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects. Undas A; Brzezinska-Kolarz B; Brummel-Ziedins K; Musial J; Szczeklik A; Mann KG J Thromb Haemost; 2005 Sep; 3(9):2015-21. PubMed ID: 16102108 [TBL] [Abstract][Full Text] [Related]
2. The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma. Shemirani AH; Haramura G; Bagoly Z; Muszbek L Biochim Biophys Acta; 2006 Aug; 1764(8):1420-3. PubMed ID: 16920044 [TBL] [Abstract][Full Text] [Related]
3. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Undas A; Sydor WJ; Brummel K; Musial J; Mann KG; Szczeklik A Circulation; 2003 Jan; 107(1):17-20. PubMed ID: 12515735 [TBL] [Abstract][Full Text] [Related]
4. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease. Stepień E; Plicner D; Kapelak B; Wypasek E; Sadowski J; Undas A Kardiol Pol; 2009 Aug; 67(8A):947-55. PubMed ID: 19784898 [TBL] [Abstract][Full Text] [Related]
5. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. Marín F; Corral J; Roldán V; González-Conejero R; del Rey ML; Sogorb F; Lip GY; Vicente V J Mol Cell Cardiol; 2004 Sep; 37(3):699-704. PubMed ID: 15350843 [TBL] [Abstract][Full Text] [Related]
6. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Ariëns RA; Philippou H; Nagaswami C; Weisel JW; Lane DA; Grant PJ Blood; 2000 Aug; 96(3):988-95. PubMed ID: 10910914 [TBL] [Abstract][Full Text] [Related]
7. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Bereczky Z; Balogh E; Katona E; Pocsai Z; Czuriga I; Széles G; Kárpáti L; Adány R; Edes I; Muszbek L Thromb Res; 2007; 120(4):567-73. PubMed ID: 17250879 [TBL] [Abstract][Full Text] [Related]
8. Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease. Bereczky Z; Balogh E; Katona E; Czuriga I; Kárpáti L; Shemirani AH; Edes I; Muszbek L Thromb Res; 2008; 121(4):469-76. PubMed ID: 17597187 [TBL] [Abstract][Full Text] [Related]
9. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. de la Red G; Tàssies D; Espinosa G; Monteagudo J; Bové A; Plaza J; Cervera R; Reverter JC Thromb Haemost; 2009 Feb; 101(2):312-6. PubMed ID: 19190815 [TBL] [Abstract][Full Text] [Related]
10. Fibrin stabilization (factor XIII), fibrin structure and thrombosis. Bereczky Z; Katona E; Muszbek L Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):430-7. PubMed ID: 15692256 [TBL] [Abstract][Full Text] [Related]
11. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Balogh I; Szôke G; Kárpáti L; Wartiovaara U; Katona E; Komáromi I; Haramura G; Pfliegler G; Mikkola H; Muszbek L Blood; 2000 Oct; 96(7):2479-86. PubMed ID: 11001900 [TBL] [Abstract][Full Text] [Related]
13. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. Kreutz RP; Bitar A; Owens J; Desta Z; Breall JA; von der Lohe E; Sinha A; Vatta M; Nystrom P; Jin Y; Flockhart DA J Thromb Thrombolysis; 2014 Oct; 38(3):380-7. PubMed ID: 24510702 [TBL] [Abstract][Full Text] [Related]
14. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Gemmati D; Serino ML; Ongaro A; Tognazzo S; Moratelli S; Resca R; Moretti M; Scapoli GL Am J Hematol; 2001 Jul; 67(3):183-8. PubMed ID: 11391716 [TBL] [Abstract][Full Text] [Related]
15. Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients. Bronić A; Ferencak G; Zadro R; Stavljenić-Rukavina A; Bernat R Mol Biol Rep; 2009 Jan; 36(1):1-5. PubMed ID: 17899444 [TBL] [Abstract][Full Text] [Related]
16. [Factor XIII in man: a review]. Dufner GS; Marbet GA Hamostaseologie; 2002 Feb; 22(1):11-9. PubMed ID: 12193980 [TBL] [Abstract][Full Text] [Related]
18. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Kobbervig C; Williams E Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253 [TBL] [Abstract][Full Text] [Related]
19. Regulation of plasma factor XIII levels in healthy individuals; a major impact by subunit B intron K c.1952+144 C>G polymorphism. Mezei ZA; Katona É; Kállai J; Bereczky Z; Molnár É; Kovács B; Ajzner É; Bagoly Z; Miklós T; Muszbek L Thromb Res; 2016 Dec; 148():101-106. PubMed ID: 27821352 [TBL] [Abstract][Full Text] [Related]